

Scancell

Update

Modi-1 successful in first part of Phase I/II trial

21 February 2023

Scancell's Modi-1 has successfully completed the monotherapy arm of the ModiFY Phase I/II trial, generating important results for the Moditope oncology vaccine platform. The first element of ModiFY showed Modi-1 was safe and well tolerated. There were encouraging, albeit early, signals of efficacy despite the advanced disease status of all patients. 23 patients have been treated to date, with 14 patients evaluated; of these 14, one has had a partial response and seven have stable disease. These data are particularly promising and support continuation into the monotherapy expansion phase and, importantly, the initiation of the checkpoint inhibitor (CPI) combination arm. The outcome of combination treatment cohorts will help define Modi-1's clinical and commercial positioning. These data drive increased confidence in the Moditope platform, leading to an uplift in our rNPV valuation to £300.1m, or 36.7p (from £269.6m, or 32.9p/share previously).

Year-end: April 30	2021	2022	2023E	2024E
Revenues (£m)	0.0	0.0	5.3	0.0
Adj. PBT (£m)	(17.7)	(11.9)	(17.6)	(24.0)
Net Income (£m)	(15.5)	(2.1)	(15.7)	(21.9)
EPS (p)	(2.28)	(0.25)	(1.93)	(2.68)
Cash (£m)	41.1	28.7	17.8	20.2
EBITDA (£m)	(8.6)	(12.6)	(13.8)	(20.2)

Source: Trinity Delta Note: Adjusted numbers exclude exceptionals

- Moditope shows early signs of efficacy** The [Phase I/II Modi-1 study](#) (ModiFY) is a two stage trial. The initial dose escalation and safety phase is followed by a number of specific patient cohorts that explore for signs of efficacy in triple negative breast cancer (TNBC), ovarian cancer, head & neck cancer, and renal cancer as both Modi-1 monotherapy and in combination with checkpoint inhibitors (CPI). A total of up to 138 patients across up to 20 UK sites will be treated, with 23 successfully vaccinated so far. Of these, 14 patients have reached the eight-week evaluation point, with no dose-limiting toxicities or safety concerns seen. Despite having failed at least one round of prior treatment and having progressive disease prior to study enrolment, one patient has a confirmed partial response and seven have stable disease.
- Progressing into combination therapy** With safety and tolerability confirmed, Modi-1 is progressing into further dose escalation as monotherapy and, importantly, initiating combination therapy with a CPI. It is data from these elements of the study that will provide multiple insights into how and where Modi-1 could be employed. The indications selected are all aggressive and difficult to treat cancers, with clear clinical needs. If the early efficacy signals seen in the first part of ModiFY are confirmed in the latter parts, this would effectively demonstrate Moditope's mode of action and would further de-risk the programme in our rNPV model.
- Raising our valuation to £300.1m, equivalent to 36.7p** We explored Scancell's investment case in detail in our recent [February 2023 Outlook](#). Increasing the probability on Moditope to 12.5% (from 10%) sees our rNPV rise to £300.1m (from £269.6m), or 36.7p/share (30.5p fully diluted). The next 12 to 18 months should see several potential value inflection points, ranging from trial results to further commercial deals. Positive outcomes should boost investor sentiment materially.

Price	18.00p
Market Cap	£147.3m
Enterprise Value	£124.4m
Shares in issue	818.4m
12 month range	10.5p-29.4p
Free float	54.4%
Primary exchange	AIM London
Other exchanges	N/A
Sector	Healthcare
Company Code	SCLP.L

Corporate client Yes



Company description

Scancell is a clinical-stage immuno-oncology specialist that has four broadly applicable technology platforms. Two are therapeutic vaccines, Moditope and ImmunoBody, and two are antibody based, GlyMab and AvidiMab.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Exhibit 1: Summary of financials

Year-end: April 30	£'000s	2020	2021	2022	2023E	2024E
INCOME STATEMENT						
Revenues		0	0	0	5,271	0
Cost of goods sold		0	0	0	0	0
Gross Profit		0	0	0	5,271	0
R&D expenses		(4,667)	(6,406)	(9,477)	(14,504)	(15,144)
General and administrative expenses		(2,115)	(3,346)	(4,787)	(5,266)	(5,792)
Underlying operating profit		(6,782)	(9,752)	(14,264)	(14,499)	(20,936)
Other revenue/expenses		0	918	965	0	0
EBITDA		(6,739)	(8,585)	(12,559)	(13,842)	(20,249)
Operating Profit		(6,782)	(8,834)	(13,299)	(14,499)	(20,936)
Interest expense		14	(1,648)	(2,878)	(2,220)	(3,041)
Other financing costs/income		0	(6,323)	12,409	(910)	0
Profit Before Taxes		(6,768)	(16,805)	(3,768)	(17,628)	(23,977)
Adj. PBT		(6,768)	(17,723)	(11,899)	(17,628)	(23,977)
Current tax income		1,262	1,328	1,703	1,895	2,031
Cumulative preferred stock dividend		0	0	0	0	0
Net Income		(5,506)	(15,477)	(2,065)	(15,733)	(21,947)
EPS (p)		(1.21)	(2.28)	(0.25)	(1.93)	(2.68)
Adj. EPS (p)		(1.21)	(2.42)	(1.25)	(1.93)	(2.68)
DPS (p)		0.00	0.00	0.00	0.00	0.00
Average no. of shares (m)		456.2	678.6	815.2	815.9	818.4
<i>Gross margin</i>		N/A	N/A	N/A	100%	N/A
BALANCE SHEET						
Current assets		5,208	44,668	32,362	21,156	23,500
Cash and cash equivalents		3,575	41,110	28,725	17,766	20,160
Accounts receivable		371	968	647	400	350
Inventories		0	0	0	0	0
Other current assets		1,262	2,590	2,990	2,990	2,990
Non-current assets		3,610	4,390	6,159	5,702	5,215
Property, plant & equipment		195	975	2,744	2,287	1,800
Other non-current assets		0	0	0	0	0
Current liabilities		(1,091)	(2,295)	(2,452)	(3,980)	(24,476)
Short-term debt		0	0	0	0	(20,000)
Accounts payable		(1,041)	(2,087)	(2,137)	(3,665)	(4,161)
Other current liabilities		(50)	(208)	(315)	(315)	(315)
Non-current liabilities		(79)	(27,278)	(17,959)	(19,909)	(19,659)
Long-term debt		0	(27,215)	(17,103)	(19,303)	(19,303)
Other non-current liabilities		(79)	(63)	(856)	(606)	(356)
Equity		7,648	19,485	18,110	2,969	(15,420)
Share capital		38,853	65,834	65,834	65,977	65,977
Other		(31,205)	(46,349)	(47,724)	(63,008)	(81,397)
CASH FLOW STATEMENTS						
Operating cash flow		(4,772)	(7,803)	(10,730)	(9,900)	(17,245)
Profit before tax		(6,768)	(16,805)	(3,768)	(17,628)	(23,977)
Non-cash adjustments		22	8,553	(8,101)	4,786	4,828
Change in working capital		143	449	372	1,775	545
Interest paid		0	0	(537)	(537)	(537)
Taxes paid		1,831	0	1,304	1,703	1,895
Investing cash flow		(13)	(741)	(1,264)	(42)	(111)
CAPEX on tangible assets		(27)	(744)	(1,268)	(200)	(200)
Other investing cash flows		14	3	4	158	89
Financing cash flow		3,800	46,079	(391)	(107)	19,750
Proceeds from equity		3,827	22,727	0	143	0
Increase in loans		0	23,506	0	0	20,000
Other financing cash flow		(27)	(154)	(391)	(250)	(250)
Net increase in cash		(985)	37,535	(12,385)	(10,959)	2,394
Cash at start of year		4,560	3,575	41,110	28,725	17,766
Cash at end of year		3,575	41,110	28,725	17,766	20,160
Net cash at end of year		3,575	13,895	11,622	(1,537)	(19,143)

Source: Company, Trinity Delta Note: Adjusted numbers exclude exceptionals.

Philippa Gardner

pgardner@trinitydelta.org

+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org

+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org

+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2023 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org